A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw
Clinicaltrials.gov identifier:
NCT04008030 (https://clinicaltrials.gov/show/NCT04008030)
People with metastatic colorectal cancer that is MSI-High
About the Study
NOTE: This study is no longer recruiting patients.
The purpose of this study is to compare the benefit of the combination of immunotherapy agents nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients who have Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer versus using nivolumab as a single therapy or chemotherapy.
This Study is Open To:
NOTE: This study is no longer recruiting patients.
This Study is Not Open To:
NOTE: This study is no longer recruiting patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.